Abstract
Sotrovimab (Xevudy; GSK and Vir Biotechnology) is no longer recommended as a first-line treatment for non-hospitalised patients with COVID-19, according to updated UK guidance. The UK-wide policy has been updated, effective immediately, following consideration of the updated COVID-19 therapeutic guideline from the World Health Organization (WHO), a review of the latest available evidence and to reflect changes in […]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
